| 词条 | Dapivirine |
| 释义 |
| drug_name = | INN = | type = | IUPAC_name = 4- |image=Dapivirine2.png | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 244767-67-7 | ATCvet = | ATC_prefix = G01 | ATC_suffix = AX17 | PubChem = 214347 | DrugBank = DB08639 | ChemSpiderID = 185837 | ChEMBL = 70663 | KEGG = D11246 | UNII = TCN4MG2VXS | chemical_formula = C20H19N5 | C= | H= | As= | Au= | Br= | Cl= | Co= | F= | Gd= | I= | Mn= | N= | Na= | O= | P= | Pt= | S= | Se= | Sr= | Tc= | Zn= | charge= | molecular_weight = 329.398 | smiles = Cc1cc(c(c(c1)C)Nc2ccnc(n2)Nc3ccc(cc3)C#N)C | StdInChI = 1S/C20H19N5/c1-13-10-14(2)19(15(3)11-13)24-18-8-9-22-20(25-18)23-17-6-4-16(12-21)5-7-17/h4-11H,1-3H3,(H2,22,23,24,25) | StdInChIKey = ILAYIAGXTHKHNT-UHFFFAOYSA-N }}Dapivirine (TMC120) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed at Janssen Therapeutics (formerly Tibotec Therapeutics).[1] The International Partnership for Microbicides (IPM) has held exclusive worldwide rights to dapivirine since 2014,[2] building upon a 2004 royalty-free license to develop dapivirine-based microbicides for women in resource-poor countries.[3] A monthly intravaginal ring containing dapivirine has been developed as a form of HIV prevention for women. Two Phase 3 clinical trials of intravaginal dapivirine rings for HIV prevention were completed in 2015 and results were announced at the 2016 Conference on Retrovirology and Opportunistic Infections (CROI). The ASPIRE Study (MTN-020) reported a 27% reduction in HIV-1 acquisition (95% CI 12-57%, p=0.007), with a trend toward greater protection in women over age 21 and no significant protection for women under age 21.[4] The Ring Study (IPM-027) reported a 31% reduction in HIV acquisition (95% CI 0.9-51.5%, p=0.040) also with a trend toward greater efficacy in women over age 21.[5] In both trials, more than 80% of returned rings showed signs of drug depletion indicating at least some use, and more than 80% of blood samples from participants in the active arm had levels of dapivirine consistent at least 8 hours of continuous use preceding the blood test. Neither trial could evaluate whether the product was used consistently between study visits. References1. ^{{Cite web|url=http://www.investor.jnj.com/releasedetail.cfm?releaseid=75177|title=Johnson & Johnson to Acquire Tibotec-Virco (NYSE:JNJ)|website=www.investor.jnj.com|access-date=2016-04-13}} {{genito-urinary-drug-stub}}2. ^{{Cite web|url=http://www.ipmglobal.org/publications/ipm-receives-worldwide-rights-hiv-prevention-medicine|title=IPM Receives Worldwide Rights to HIV Prevention Medicine|last=hseltzer|website=www.ipmglobal.org|access-date=2016-04-13}} 3. ^{{Cite web|url=http://www.ipmglobal.org/our-work/products-development/dapivirine-tmc120|title=Dapivirine (TMC120)|last=ipm-admin|website=www.ipmglobal.org|access-date=2016-04-13}} 4. ^{{Cite web|url=http://www.croiwebcasts.org/console/player/29584|title=A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women|author=Jared M. Baeten|access-date=2016-04-13}} 5. ^{{Cite web|url=http://www.croiwebcasts.org/console/player/29585|title=Safety and Efficacy of Dapivirine Vaginal Ring for HIV-1 Prevention in African Women|author=Annalene Nel|access-date=2016-04-13}} 1 : Reverse transcriptase inhibitors |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。